Focused On-demand Library for Lysosomal acid lipase/cholesteryl ester hydrolase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Cholesteryl esterase; Lipase A; Sterol esterase

Alternative UPACC:

P38571; B2RBH5; D3DR29; Q16529; Q53H21; Q5T074; Q5T771; Q96EJ0


Lysosomal acid lipase/cholesteryl ester hydrolase, also known as Cholesteryl esterase, Lipase A, and Sterol esterase, plays a pivotal role in lipid metabolism. It catalyzes the deacylation of triacylglyceryl and cholesteryl ester core lipids of endocytosed low-density lipoproteins, generating free fatty acids and cholesterol.

Therapeutic significance:

The enzyme's deficiency is linked to severe metabolic disorders, including Wolman disease and Cholesteryl ester storage disease. Wolman disease, a fatal condition in infancy, and Cholesteryl ester storage disease, a late-onset disorder, both result from the accumulation of cholesteryl esters and triglycerides due to LIPA gene variants.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.